Pascal and Francis Bibliographic Databases


Search results

Your search


Document Type [dt]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV


A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 237

  • Page / 10

Selection :

  • and

Optimal duration of Eptifibatide infusion in percutaneous coronary intervention (an ESPRIT Substudy)REBEIZ, Abdallah G; DERY, Jean-Pierre; JOSEPH, Diane et al.The American journal of cardiology. 2004, Vol 94, Num 7, pp 926-929, issn 0002-9149, 4 p.Article

Unexpected flow cytometric results with two small GPIIb/IIIa blockers : Eptifibatide and tirofibanHEZARD, Nathalie; METZ, Damien; TASSAN-MANGINA, Sophie et al.Thrombosis and haemostasis. 2001, Vol 85, Num 3, pp 561-562, issn 0340-6245Article

A novel method to assess platelet inhibition by eptifibatide with Thrombelastograph®KATORI, Nobuyuki; SZLAM, Fania; LEVY, Jerrold H et al.Anesthesia and analgesia. 2004, Vol 99, Num 6, pp 1794-1799, issn 0003-2999, 6 p.Article

Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofibanMARCINIAK, Stanley J; JORDAN, Robert E; MASCELLI, Mary A et al.Thrombosis and haemostasis. 2001, Vol 85, Num 3, pp 539-543, issn 0340-6245Article

In vitro dose response to different GPIIb/IIIa-antagonists : Inter-laboratory comparison of various platelet function testsHARDER, S; KLINKHARDT, U; BREDDIN, H. K et al.Thrombosis research. 2001, Vol 102, Num 1, pp 39-48, issn 0049-3848Article

Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjectsHOLMES, M. B; SOBEL, B. E; SCHNEIDER, D. J et al.The American journal of cardiology. 1999, Vol 84, Num 2, pp 203-207, issn 0002-9149Article

Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromesGREENBAUM, Adam B; HARRINGTON, Robert A; LINCOFF, A. Michael et al.Journal of the American College of Cardiology. 2001, Vol 37, Num 2, pp 492-498, issn 0735-1097Article

Association of Eptifibatide and acute profound thrombocytopeniaHONGO, Richard H; BRENT, Bruce N.The American journal of cardiology. 2001, Vol 88, Num 4, pp 428-431, issn 0002-9149Article

Eptifibatide-Induced Thrombocytopenia and Subsequent ThrombosisGIULIANO, Christopher; EDWIN, Stephanie B; KADOR, Hani et al.The Journal of pharmacy technology. 2012, Vol 28, Num 4, pp 146-150, issn 8755-1225, 5 p.Article

Incidence of Bleeding in Renally Impaired Patients Receiving Incorrectly Dosed Eptifibatide or Bivalirudin While Undergoing Percutaneous Coronary InterventionTAYLOR, Lindsey A; MAURO, Vincent F.The Annals of pharmacotherapy. 2012, Vol 46, Num 1, pp 35-41, issn 1060-0280, 7 p.Article

Improved liquid chromatography-tandem mass spectrometry method for the analysis of eptifibatide in human plasmaZHOU, Zhi-Ling; YU, Xi-Yong; LI, Xiao-Hong et al.Journal of chromatography. B. 2010, Vol 878, Num 23, pp 2094-2100, issn 1570-0232, 7 p.Article

Intracoronary Eptifibatide Bolus Administration During Percutaneous Coronary Revascularization for Acute Coronary Syndromes With Evaluation of Platelet Glycoprotein IIb/IIIa Receptor Occupancy and Platelet Function: The Intracoronary Eptifibatide (ICE) TrialDEIBELE, Albert J; JENNINGS, Lisa K; TCHENG, James E et al.Circulation (New York, N.Y.). 2010, Vol 121, Num 6, pp 784-791, issn 0009-7322, 8 p.Article

Balancing safety and efficacy: recent clinical evidence optimizing outcomes in patients with intermediate to high-risk non-ST-segment elevated acute coronary syndromeVALGIMIGLI, Marco.European heart journal supplements. 2010, Vol 12, Num D, issn 1520-765X, D14-D23Article

Determination of eptifibatide concentration in human plasma utilizing the liquid chromatography-tandem mass spectrometry methodJIA LIU; XIAOTAO DUAN; XIAOYAN CHEN et al.Journal of chromatography. B. 2009, Vol 877, Num 5-6, pp 527-532, issn 1570-0232, 6 p.Article

Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting : Insights from the enhanced suppression of the platelet IIb/IIIa receptor with integrilin therapy (ESPRIT) trial. CommentaryPUMA, Joseph A; BANKO, Lesan T; PIEPER, Karen S et al.Journal of the American College of Cardiology. 2006, Vol 47, Num 4, pp 715-720, issn 0735-1097, 6 p.Article

Tolerability and feasibility of eptifibatide in acute coronary syndrome in patients at high risk for cardiovascular disease : A retrospective analysisAZZAM, Zaher S; SA'AD, Elias; JABAREEN, Amal et al.Current therapeutic research. 2005, Vol 66, Num 6, pp 501-510, issn 0011-393X, 10 p.Article

Combined effects of melagatran and eptifibatide on platelet aggregation inhibition but not thrombin generation inhibitionKOESTENBERGER, Martin; GALLISTL, Siegfried; CVIRN, Gerhard et al.Blood coagulation & fibrinolysis. 2004, Vol 15, Num 2, pp 131-137, issn 0957-5235, 7 p.Article

Improved speed and stability of st-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose Tenecteplase for Acute ST-segment elevation myocardial infarctionROE, Matthew T; GREEN, Cynthia L; HARRINGTON, Robert A et al.Journal of the American College of Cardiology. 2004, Vol 43, Num 4, pp 549-556, issn 0735-1097, 8 p.Article

Incidence and time course of thrombocytopenla with Abciximab and Eptifibatide in patients undergoing percutaneous coronary interventionFAHDI, Ibrahim E; SAUCEDO, Jorge F; HENNEBRY, Thomas et al.The American journal of cardiology. 2004, Vol 93, Num 4, pp 453-455, issn 0002-9149, 3 p.Article

Short-term intravenous eptifibatide infusion combined with reduced dose recombinant tissue plasminogen activator inhibits platelet recruitment at sites of coronary artery injuryRUBENSTEIN, Mark H; FINN, Aloke V; LEINBACH, Robert C et al.Journal of the American College of Cardiology. 2004, Vol 43, Num 2, pp 287-294, issn 0735-1097, 8 p.Article

Thrombopénies induites par les antagonistes du complexe GPIIbIIIa plaquettaire administrés par voie injectable = Anti-GPIIbIIIa induced thrombocytopeniaLE BELLER, Christine; ALHENC-GELAS, Martine.Hématologie (Montrouge). 2004, Vol 10, Num 1, pp 14-23, issn 1264-7527, 10 p.Article

Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation Myocardial Infarction: Results of the integrilin and tenecteplase in acute myocardial Infarction (integriti) phase II angiographic trial. CommentaryGIUGLIANO, Robert P; ROE, Matthew T; GREENBERG, Sally et al.Journal of the American College of Cardiology. 2003, Vol 41, Num 8, pp 1251-1263, issn 0735-1097, 13 p.Article

Eptifibatide-induced acute profound thrombocytopenia presenting as refractory hypotensionREZKALLA, Shereif H; HAYES, John J; CURTIS, Brian R et al.Catheterization and cardiovascular interventions. 2003, Vol 58, Num 1, pp 76-79, issn 1522-1946, 4 p.Article

Rationale for the early use of platelet glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromesREBEIZ, Abdallah G; ROE, Matthew T.Cardiovascular reviews & reports. 2003, Vol 24, Num 3, pp 128-134, issn 0197-3118, 7 p.Article

Évaluation de l'utilisation d'un inhibiteur de la glycoprotéine IIbIIIa, l'integrilin®, dans un service de cardiologie = Evaluation of a glycoprotein iibiiia receptor inhibitor (Integrilin®) in a cardiology unitWOLFF, E; PISANTE, L; MICHAUD, P et al.Journal de pharmacie clinique (Paris). 2003, Vol 22, Num 2, pp 64-68, issn 0291-1981, 5 p.Article

  • Page / 10